HPLC purity
Reverse-phase HPLC with UV detection; purity target reported per lot with related-substance reporting on request.
Pepti · Catalog · Tesamorelin + Ipamorelin Blend (10mg / 5mg)
Growth-hormone-axis blend · research-use
A single-vial co-lyophilate of stabilized-GHRH tesamorelin and selective-secretagogue ipamorelin, batch-documented by HPLC and MS for research and private-label programs.
Vial illustrations reflect supplied lyophilized format. Distribution scope and destination market confirmed before invoicing.
| Compound | Tesamorelin + Ipamorelin Blend (10mg / 5mg) |
|---|---|
| Form | Lyophilized powder, glass vial |
| Purity target | ≥ 99% by HPLC |
| Vial formats | 15mg |
| Documentation | Batch-linked COA + HPLC chromatogram + MS identity record for every production lot |
| Distribution scope | Research use, worldwide |
| Storage | Store lyophilized powder sealed at -20°C, protected from light and moisture; brief ambient transit is tolerated. After reconstitution, keep refrigerated at 2-8°C and use within the validated stability window. For laboratory research use only — not for consumer or veterinary use. |
| Tier | Quantity | Lead time |
|---|---|---|
| OEM lot | 50 kits (500 vials) | 3–7 days |
| Production lot | 500–1,000 vials | 10–14 days |
| OEM repeat | 1,000+ vials | 14–18 days, scheduled |
Supplied as a research-use peptide. Every quote confirms current-batch COA, purity, destination market and buyer track before invoicing.
Overview
A co-formulated research blend pairing tesamorelin, a 44-amino-acid DPP-IV-resistant analog of growth-hormone-releasing hormone (GHRH), with ipamorelin, a selective pentapeptide agonist of the ghrelin / growth-hormone-secretagogue (GHS) receptor. In research models the two components engage complementary nodes of the somatotropic axis — GHRH-receptor signaling and GHS-receptor signaling.
Documentation
batch-linked COA, HPLC chromatogram and MS identity record for every production lot. Distribution scope confirmed before invoicing.
Reverse-phase HPLC with UV detection; purity target reported per lot with related-substance reporting on request.
Mass spectrometry identity confirmation against the Tesamorelin + Ipamorelin Blend (10mg / 5mg) reference profile.
Compound prefix and lot serial printed on the vial label and repeated in the document pack and carton.
FAQ
Each vial is co-lyophilized with 10 mg tesamorelin and 5 mg ipamorelin (15 mg total peptide) as a single mixed powder, not as two separate vials. The exact component identities and ratio are stated on the batch certificate of analysis.
No. A blend is a physical mixture, so it carries no single CAS number, molecular formula, or molecular weight. Documentation references each component's own identifiers instead: tesamorelin (CAS 218949-48-5, C221H366N72O67S, ~5135.9 g/mol) and ipamorelin (CAS 170851-70-4, C38H49N9O5, ~711.9 g/mol).
Every production lot includes a batch-linked certificate of analysis reporting HPLC purity and mass-spectrometry (MS) identity for both components. Additional third-party verification and testing (residual solvents, endotoxin (only if specifically ordered and tested), water content) can be arranged on request.
The standard format is a 15 mg vial (10 mg tesamorelin / 5 mg ipamorelin) at an MOQ of 50 kits (500 vials). Alternate ratios, fill weights, custom labeling, and private-label kitting are quoted on RFQ.
It ships as a sterile-filtered lyophilized powder under cold-chain, with COA and, where required, export documentation. Material is supplied for laboratory and manufacturing research use only; buyers are responsible for compliance with import and end-use regulations in their jurisdiction.
Related compounds